Dec 09, 2021
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
Dec 06, 2021
Brii Biosciences Included in Hong Kong Stock Connect
